Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
Status:
Not yet recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Can Semaglutide help reduce the damage caused by a stroke? ASSET trial is a national,
multicenter, clinical trial, investigating the safety and efficacy of Semaglutide in
non-diabetic patients with acute ischemic stroke.
Stroke is a worldwide leading cause of long-term disability and death. In the most common
type of stroke (ischemic stroke), a blood clot obstructs an artery in the brain, and thereby
prevents oxygenated blood from reaching an area of the brain. Brain cells are particularly
vulnerable to the lack of oxygen. In the areas most severely affected by a stroke, brain
cells die after 5 minutes. As more time pass, the affected area expands, and more brain cells
perish. Today, efficient treatments aiming at reestablishing the flow of blood by either
breaking down the blood clot (thrombolysis) or removing the clot (thrombektomi) are used.
However, a significant amount of patients undergoing succesful treamtent, still suffer
permanent disability following an ischemic stroke.
Semaglutide mimics a naturally occurring hormone (glucagon-like peptide-1) and is currently
used to treat diabetes and obesity. However, semaglutide has also been shown to possess
neuroprotective abilities in recent animal studies, where it reduced the damage caused by
ischemic stroke in rats. This study sets out to investigate if it's possible to utilize
Semaglutide, to increase the resilience of brain cells in patients with an acute ischemic
stroke, with the aim of bettering their outcome.
The participants consist of non-diabetic patients with acute ischemic stroke, who will be
randomized to:
- Treatment with subcutaneous Semaglutide, or
- No additional treatment (control group)
Both groups will be treated according to the standard national guidelies for acute ischemic
stroke.
The two groups will then be compared to see, if patients in the group treated with
Semaglutide are less impacted by their stroke.
Phase:
Phase 2
Details
Lead Sponsor:
Aarhus University Hospital
Collaborators:
Aalborg University Hospital Bispebjerg Hospital Glostrup University Hospital, Copenhagen Herning Hospital Novo Nordisk A/S Odense University Hospital Rigshospitalet, Denmark